Surrogate (Q27933): Difference between revisions
From MaRDI portal
EloiFerrer (talk | contribs) Changed an Item |
EloiFerrer (talk | contribs) Removed claim: Property:P1457: In a clinical trial, it frequently occurs that the most credible outcome to evaluate the effectiveness of a new therapy (the true endpoint) is difficult to measure. In such a situation, it can be an effective strategy to replace the true endpoint by a (bio)marker that is easier to measure and that allows for a prediction of the treatment effect on the true endpoint (a surrogate endpoint). The package 'Surrogate' allows for an evalua... |
||
| Property / P1457 (Deleted Property) | |||
| Property / P1457 (Deleted Property): In a clinical trial, it frequently occurs that the most credible outcome to evaluate the effectiveness of a new therapy (the true endpoint) is difficult to measure. In such a situation, it can be an effective strategy to replace the true endpoint by a (bio)marker that is easier to measure and that allows for a prediction of the treatment effect on the true endpoint (a surrogate endpoint). The package 'Surrogate' allows for an evaluation of the appropriateness of a candidate surrogate endpoint based on the meta-analytic, information-theoretic, and causal-inference frameworks. Part of this software has been developed using funding provided from the European Union's Seventh Framework Programme for research, technological development and demonstration (Grant Agreement no 602552), the Special Research Fund (BOF) of Hasselt University (BOF-number: BOF2OCPO3), GlaxoSmithKline Biologicals, Baekeland Mandaat (HBC.2022.0145), and Johnson & Johnson Innovative Medicine. Property P1457 not found, cannot determine the data type to use. / rank | |||
Latest revision as of 07:50, 19 April 2024
Evaluation of Surrogate Endpoints in Clinical Trials
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Surrogate |
Evaluation of Surrogate Endpoints in Clinical Trials |
Statements
20 February 2024
0 references
expanded from: GPL (≥ 2) (English)
0 references
In a clinical trial, it frequently occurs that the most credible outcome to evaluate the effectiveness of a new therapy (the true endpoint) is difficult to measure. In such a situation, it can be an effective strategy to replace the true endpoint by a (bio)marker that is easier to measure and that allows for a prediction of the treatment effect on the true endpoint (a surrogate endpoint). The package 'Surrogate' allows for an evaluation of the appropriateness of a candidate surrogate endpoint based on the meta-analytic, information-theoretic, and causal-inference frameworks. Part of this software has been developed using funding provided from the European Union's Seventh Framework Programme for research, technological development and demonstration (Grant Agreement no 602552), the Special Research Fund (BOF) of Hasselt University (BOF-number: BOF2OCPO3), GlaxoSmithKline Biologicals, Baekeland Mandaat (HBC.2022.0145), and Johnson & Johnson Innovative Medicine.
0 references
